Dupilumab is a game-changer for people with severe eczema. It's the first biologic drug approved for this condition. This means it's made from living organisms, not chemicals. It works by targeting specific parts of the immune system that cause inflammation. Eczema is a long-term skin condition. It
In the world of medicine, there's a big push to make drugs more affordable. This push has led to the creation of biosimilar policies. These policies are designed to encourage the use of biosimilars, which are basically cheaper copies of expensive biologics. The goal? To save money and make healthcar
Psoriasis, a long-term skin disorder causing red, scaly patches, is on the rise globally. However, not many studies have looked into how it's treated and the impact it has on healthcare in places like Germany. Let's dive into some real-world data to understand what's going on. In Germany, a specifi
Have you ever heard of an ear infection called eosinophilic otitis media (EOM)? It’s tough to treat, and it often goes hand in hand with conditions like eosinophilic chronic rhinosinusitis (ECRS) and asthma. These conditions are all caused by something called type 2 inflammations. Recently, a specia
Biologics have become a crucial treatment for severe chronic rhinosinusitis with nasal polyps (CRSwNP). These medicines work by stopping type 2 inflammation. But doctors often face challenges when they need to document patient histories and current findings to show why biologics are necessary. This
Psoriasis patients often worry about developing psoriatic arthritis (PsA). But which biologic treatment is best? Researchers looked at three types: IL-23 inhibitors, IL-17 inhibitors, and IL-12/23 inhibitors, comparing them to TNF inhibitors. The goal? To see who's at higher risk for PsA. First, le
